Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00651911 |
An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome
Condition | Intervention | Phase |
---|---|---|
Tumor Lysis Syndrome |
Drug: urate oxidase |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome |
Enrollment: | 45 |
Study Start Date: | July 2003 |
Study Completion Date: | July 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | sanofi-aventis ( Study Director ) |
Study ID Numbers: | L_8637 |
Study First Received: | March 28, 2008 |
Last Updated: | March 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00651911 History of Changes |
Health Authority: | Taiwan: Department of Health |
Lymphatic Diseases Uric Acid Immunoproliferative Disorders Tumor Lysis Syndrome |
Antirheumatic Agents Lymphoproliferative Disorders Rasburicase |
Disease Immunoproliferative Disorders Immune System Diseases Rasburicase Gout Suppressants Pharmacologic Actions Lymphatic Diseases |
Pathologic Processes Syndrome Therapeutic Uses Tumor Lysis Syndrome Lymphoproliferative Disorders Antirheumatic Agents |